In the past week, OCGN stock has gone down by -1.48%, with a monthly decline of -10.28% and a quarterly plunge of -41.68%. The volatility ratio for the week is 4.77%, and the volatility levels for the last 30 days are 6.15% for Ocugen Inc The simple moving average for the past 20 days is -3.36% for OCGN’s stock, with a -25.27% simple moving average for the past 200 days.
Is It Worth Investing in Ocugen Inc (NASDAQ: OCGN) Right Now?
Company’s 36-month beta value is 3.74.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for OCGN is 283.71M, and currently, short sellers hold a 17.84% ratio of that floaft. The average trading volume of OCGN on October 22, 2024 was 3.95M shares.
OCGN) stock’s latest price update
Ocugen Inc (NASDAQ: OCGN)’s stock price has dropped by -0.56 in relation to previous closing price of 0.94. Nevertheless, the company has seen a loss of -1.48% in its stock price over the last five trading days. globenewswire.com reported 2024-10-22 that MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial recently convened and approved enrollment for the second phase of the Phase 1/2 clinical trial. OCU410ST (AAV5-hRORA) is a novel modifier gene therapy candidate being developed for Stargardt disease.
Analysts’ Opinion of OCGN
Many brokerage firms have already submitted their reports for OCGN stocks, with Maxim Group repeating the rating for OCGN by listing it as a “Buy.” The predicted price for OCGN in the upcoming period, according to Maxim Group is $4 based on the research report published on October 15, 2024 of the current year 2024.
Chardan Capital Markets, on the other hand, stated in their research note that they expect to see OCGN reach a price target of $3.50. The rating they have provided for OCGN stocks is “Buy” according to the report published on March 01st, 2023.
Mizuho gave a rating of “Buy” to OCGN, setting the target price at $5 in the report published on August 23rd of the previous year.
OCGN Trading at -16.43% from the 50-Day Moving Average
After a stumble in the market that brought OCGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.67% of loss for the given period.
Volatility was left at 6.15%, however, over the last 30 days, the volatility rate increased by 4.77%, as shares sank -4.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.94% lower at present.
During the last 5 trading sessions, OCGN fell by -1.09%, which changed the moving average for the period of 200-days by +40.03% in comparison to the 20-day moving average, which settled at $0.9657. In addition, Ocugen Inc saw 62.28% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OCGN starting from RAMESH KUMAR, who proposed sale 116,705 shares at the price of $1.25 back on Aug 16 ’24. After this action, RAMESH KUMAR now owns shares of Ocugen Inc, valued at $145,905 using the latest closing price.
Stock Fundamentals for OCGN
Current profitability levels for the company are sitting at:
- -6.31 for the present operating margin
- 0.86 for the gross margin
The net margin for Ocugen Inc stands at -6.21. The total capital return value is set at -2.29. Equity return is now at value -120.03, with -80.82 for asset returns.
Based on Ocugen Inc (OCGN), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -13.71. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -41.27.
Currently, EBITDA for the company is -64.83 million with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of 31.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.04.
Conclusion
In a nutshell, Ocugen Inc (OCGN) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
